---
title: "Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296142234.md"
description: "Zentalis Pharmaceuticals closed an underwritten public offering on August 17, 2026, selling 29.9 million shares at $3.50 each for approximately $92.6 million in gross proceeds. The company sold all shares to advance the late-stage development of its WEE1 inhibitor, azenosertib, for ovarian cancer treatment."
datetime: "2026-08-17T20:02:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296142234.md)
  - [en](https://longbridge.com/en/news/296142234.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296142234.md)
generator: "portal-rs"
---

# Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

On August 17, 2026, Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL) completed an underwritten public offering of its common stock, selling 26,450,000 shares, with an additional 3,450,000 shares sold through the underwriters' option exercise. Priced at $3.50 per share, the total gross proceeds amounted to around $92.6 million before deductions for underwriting discounts, commissions, and offering expenses. The Company solely sold all the shares in this public offering, advancing its late-stage development of the WEE1 inhibitor, azenosertib, for ovarian cancer treatment with a biomarker-driven approach.

### Related Stocks

- [ZNTL.US](https://longbridge.com/en/quote/ZNTL.US.md)

## Related News & Research

- [Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ZNTL Stock News](https://longbridge.com/en/news/297700781.md)
- [Zentalis grants 269,000 inducement stock options to four new hires at $3.71 each](https://longbridge.com/en/news/297700247.md)
- [Faron Pharmaceuticals Ltd: Holding(s) In Company](https://longbridge.com/en/news/298025632.md)
- [Zentalis Pharmaceuticals to present at Morgan Stanley global healthcare investor conference](https://longbridge.com/en/news/297824490.md)
- [Curanex Pharmaceuticals executes 1-for-20 reverse stock split](https://longbridge.com/en/news/298072376.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**